Humana (NYSE:HUM) Rating Lowered to Equal Weight at Stephens

Stephens cut shares of Humana (NYSE:HUM) from an overweight rating to an equal weight rating in a research report sent to investors on Wednesday, Marketbeat reports. Stephens currently has $250.00 price target on the insurance provider’s stock, down from their prior price target of $400.00.

HUM has been the topic of several other research reports. Morgan Stanley assumed coverage on Humana in a research report on Monday, June 24th. They set an equal weight rating and a $374.00 target price on the stock. Truist Financial lifted their price objective on shares of Humana from $355.00 to $400.00 and gave the stock a hold rating in a report on Monday, July 15th. Piper Sandler began coverage on shares of Humana in a report on Wednesday, June 26th. They issued an overweight rating and a $392.00 target price for the company. JPMorgan Chase & Co. boosted their price target on shares of Humana from $332.00 to $396.00 and gave the stock a neutral rating in a report on Wednesday, August 21st. Finally, Deutsche Bank Aktiengesellschaft upped their price objective on shares of Humana from $341.00 to $349.00 and gave the stock a hold rating in a research report on Friday, August 2nd. One analyst has rated the stock with a sell rating, sixteen have given a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of Hold and a consensus price target of $357.24.

Humana Stock Performance

Shares of HUM stock opened at $240.03 on Wednesday. The company has a current ratio of 1.66, a quick ratio of 1.66 and a debt-to-equity ratio of 0.70. The firm has a fifty day simple moving average of $337.70 and a two-hundred day simple moving average of $342.66. Humana has a 12 month low of $213.31 and a 12 month high of $530.54. The firm has a market capitalization of $28.92 billion, a PE ratio of 14.95, a price-to-earnings-growth ratio of 2.44 and a beta of 0.50.

Humana (NYSE:HUM) last posted its earnings results on Wednesday, July 31st. The insurance provider reported $6.96 EPS for the quarter, topping the consensus estimate of $5.89 by $1.07. Humana had a net margin of 1.53% and a return on equity of 16.12%. The company had revenue of $29.54 billion during the quarter, compared to the consensus estimate of $28.52 billion. During the same period in the previous year, the firm posted $8.94 earnings per share. The firm’s revenue for the quarter was up 10.4% on a year-over-year basis. Analysts forecast that Humana will post 16.01 EPS for the current fiscal year.

Humana Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Monday, September 30th will be given a $0.885 dividend. This represents a $3.54 annualized dividend and a dividend yield of 1.47%. The ex-dividend date of this dividend is Monday, September 30th. Humana’s dividend payout ratio (DPR) is presently 22.04%.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in HUM. CarsonAllaria Wealth Management Ltd. lifted its holdings in shares of Humana by 111.4% in the second quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock worth $28,000 after buying an additional 39 shares in the last quarter. Hantz Financial Services Inc. purchased a new stake in Humana in the 2nd quarter worth approximately $35,000. Family Firm Inc. bought a new position in Humana in the 2nd quarter valued at $37,000. Hollencrest Capital Management purchased a new position in shares of Humana during the 2nd quarter valued at $40,000. Finally, Riverview Trust Co purchased a new position in shares of Humana during the 2nd quarter valued at $44,000. Hedge funds and other institutional investors own 92.38% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.